



Protein Post-Translational Modifications and Protein Aggregation in Neurodegenerative Diseases

Guest Editor:

Dr. Wayne G. Carter

Clinical Toxicology Research
Group, School of Medicine,
University of Nottingham,
Nottingham, UK

Deadline for manuscript
submissions:
closed (25 March 2020)

Message from the Guest Editor

Dear Colleagues,

Undesired or aberrant protein aggregation is common to a number of neurodegenerative diseases, with accumulation of aggregated proteins thought to be neurotoxic. Examples include: A β or tau protein aggregates in Alzheimer's disease; α -synuclein deposits within Lewy bodies (LBs) in Parkinson's disease, multiple system atrophy, and dementia with LBs; and poly-glutamine tracts in Huntington's disease. A growing area of research in neurodegenerative disease focusses upon how PTMs promote protein aggregation, and how modified and aggregated proteins may be resistant to degradation or removal by cellular machinery including proteasomal or autophagic mechanisms. The importance of protein PTMs and associated protein aggregation are underscored by current clinical research to develop drugs or biological therapies with anti-(protein)aggregation properties. This special issue will broadly cover PTMs that may influence protein aggregation, methods to detect aggregated proteins, and the relationship between protein aggregation and the pathogenesis or progression of neurodegenerative diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience,
University of Pittsburgh,
Pittsburgh, PA 15260, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2025).

Contact Us

Brain Sciences Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/brainsci
brainsci@mdpi.com
[X@BrainSci_MDPI](https://twitter.com/BrainSci_MDPI)